Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
764.480.02%
QQQ
714.89-
BTC/USD
77102.000.1371%
DIA
525.910.02%
GLD
398.290.12%
TLT
80.930.07%

Lyell Immunopharma Inc

LYELNASDAQ
Trade with Public
Trade with Public
$11.96
-0.24-1.97%
At close: Sep 11, 5:00 PM EST
$11.96
N/A
After Hours: 4:00 PM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

Lyell Immunopharma Analyst Price Targets

Wall Street analyst price targets and consensus rating for Lyell Immunopharma (LYEL).

Price Target Range — 12 Quarters

Analyst Consensus — 7 Analysts

1S.Buy
5Buy
1Sell
Consensus RatingBuy# Analysts7Avg. Consensus PT$32Upside to Avg. PT+164.5%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Sep 11, 2026NeedhamGil BlumMaintainedBuy$44
Aug 6, 2026StifelStephen WilleyInitiateBuy$36
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Needham Reiterates Buy on Lyell Immunopharma, Maintains $44 Price Target

Needham analyst Gil Blum reiterates Lyell Immunopharma (NASDAQ:LYEL) with a Buy and maintains $44 price target.
Benzinga Newsdesk

This Lyell Immunopharma Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday

Wall Street analysts change outlook on top names. Check analyst ratings page for all changes. See what analysts say about LYEL, IMRX, and RNA.
Avi Kapoor

PRO
Stifel Initiates Coverage On Lyell Immunopharma with Buy Rating, Announces Price Target of $36

Stifel analyst Stephen Willey initiates coverage on Lyell Immunopharma (NASDAQ:LYEL) with a Buy rating and announces Price Target of $36.
Benzinga Newsdesk

PRO
B. Riley Securities Initiates Coverage On Lyell Immunopharma with Buy Rating, Announces Price Target of $44

B. Riley Securities analyst Yuan Zhi initiates coverage on Lyell Immunopharma (NASDAQ:LYEL) with a Buy rating and announces Price Target of $44.
Benzinga Newsdesk

PRO
Citizens Reiterates Market Outperform on Lyell Immunopharma, Maintains $34 Price Target

Citizens analyst Reni J. Benjamin reiterates Lyell Immunopharma (NASDAQ:LYEL) with a Market Outperform and maintains $34 price target.
Benzinga Newsdesk

PRO
Needham Reiterates Buy on Lyell Immunopharma, Maintains $44 Price Target

Needham analyst Gil Blum reiterates Lyell Immunopharma (NASDAQ:LYEL) with a Buy and maintains $44 price target.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved